我武生物(300357) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥231,630,605.75, reflecting a year-on-year growth of 2.64%[8] - Net profit attributable to shareholders was ¥122,075,459.45, representing a 5.14% increase compared to the same period last year[8] - Basic earnings per share for the reporting period were ¥0.2332, up by 5.19% compared to the previous year[8] - The company reported a net profit of approximately ¥629.19 million, a significant increase from ¥494.30 million, reflecting a growth of around 27% year-over-year[46] - Net profit for the current period was 119,313,074.75, compared to 114,131,251.78 in the previous period, showing an increase of about 4.8%[58] - The total profit for the current period is 155,518,119.24, compared to 142,673,882.50 in the previous period, indicating an increase of around 8.9%[62] - The net profit for the current period is ¥132,570,783.99, up from ¥121,649,888.13 in the previous period, representing an increase of about 9.9%[62] - Net profit for the current period is ¥249,385,642.81, a decrease of 2.67% compared to ¥255,072,647.21 in the previous period[77] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,562,152,170.56, an increase of 9.38% compared to the end of the previous year[8] - Current assets totaled approximately ¥1.15 billion, up from ¥1.05 billion, indicating an increase of around 10% year-over-year[37] - Total liabilities amounted to approximately ¥81.07 million, compared to ¥76.25 million, marking an increase of around 6%[43] - Total liabilities increased to 72,044,126.91 from 66,931,968.97, marking an increase of about 7.5%[56] - Total assets amounted to 1,444,504,620.60, up from 1,284,251,939.85, indicating an increase of approximately 12.5%[56] - The company's total equity attributable to shareholders reached approximately ¥1.41 billion, up from ¥1.27 billion, indicating a growth of about 10%[46] Cash Flow - The net cash flow from operating activities was ¥70,045,926.56, showing a significant increase of 29.69% year-on-year[8] - Net cash flow from financing activities decreased by ¥158,025,120.00, down 247.77% year-on-year, mainly due to reduced cash received from minority shareholder investments in subsidiaries[23] - Net increase in cash and cash equivalents decreased by ¥124,004,235.10, down 74.78% year-on-year, due to a decrease in cash flow from financing activities and an increase in cash flow from operating activities[23] - Cash flow from operating activities generated a net amount of ¥191,327,232.19, an increase from ¥157,551,183.19 in the previous period[80] - Cash and cash equivalents at the end of the period totaled ¥191,638,285.30, down from ¥625,860,419.05 in the previous period[82] Research and Development - R&D expenses increased by ¥18,334,042.06, a growth of 70.09% year-on-year, mainly due to continued investment in existing R&D projects such as stem cells[22] - Research and development expenses rose to 19,595,994.02 from 12,102,332.46, representing an increase of approximately 61.8%[56] - Research and development expenses increased to ¥16,156,709.96, up 49.73% from ¥10,829,800.92 in the previous period[74] - The company plans to continue expanding its R&D efforts and product offerings in the future[22] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,485, with the largest shareholder holding 38.86% of the shares[11] - The company did not engage in any repurchase transactions during the reporting period[14] - There are no non-operating fund occupations by controlling shareholders and their related parties during the reporting period[30] Government Subsidies - The company received government subsidies amounting to ¥10,244,888.84 during the reporting period, primarily from the Huzhou Mogan Mountain High-tech Industrial Development Zone[10] - Non-operating income increased by ¥6,771,819.20, up 189.60% year-on-year, mainly due to an increase in government subsidies received[22] Financial Standards and Compliance - The company has no violations of external guarantees during the reporting period[29] - The company has implemented new revenue and leasing standards starting from 2020, necessitating adjustments in financial reporting[90] - The company executed the new revenue recognition standards starting January 1, 2020[100]